Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.5. The key difference: State Street SPDR Bloomberg 1-3 Month T-Bill ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BIL | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Fixed Income |
52-Week High | $491.22 | $91.77 |
52-Week Low | $278.09 | $91.27 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BIL (SPDR Bloomberg 1-3 Month T-Bill ETF) trades at $91.50 with minimal daily movement, reflecting its stable Treasury bill portfolio. The ETF maintains consistent $0.27 quarterly dividends and shows bearish technical signals despite neutral oscillators. Recent market focus compares short-term Treasury ETFs like BIL against money market alternatives as investors seek yield amid Federal Reserve policy uncertainty.
BIL offers low-risk cash parking with Treasury bill exposure, but faces pressure from potential Fed rate hikes that could impact short-term yields. The ETF's stability appeals to risk-averse investors, though higher-yielding alternatives may emerge if rates rise further. Current technical weakness suggests cautious near-term positioning despite fundamental safety.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →
